Recent Press Releases

Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501

Supported By Phase 3 Studies in Moderate-to-Severe Plaque Psoriasis and Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Dec. 4, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced...

Sun Pharma announces US FDA approval for generic Gleevec®

Company eligible for 180-days marketing exclusivity on a first-to-file Para-IV ANDA Mumbai, December 04, 2015: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA,...

Samsung Bioepis' RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea

INCHEON, Korea – December 4, 2015 – Samsung Bioepis Co., Ltd. today announced that Korea's Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version...

Teva Announces Pricing of Public Offerings of American Depositary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Actavis Generics

JERUSALEM--()--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has priced its concurrent offerings totaling $6.75 billion, consisting of 54 million...

EISAI TO ACQUIRE CHINESE GENERIC PHARMACEUTICAL COMPANY LIAONING TIANYI BIOLOGICAL PHARMACEUTICAL CO., LTD.

STRENGTHENING BUSINESS PLATFORM IN CHINA TO ADDRESS DIVERSE MEDICAL NEEDS Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its China holding company Eisai China...

Cummings Criticizes Fake "Price Cut" for Critical Drug

FOR IMMEDIATE RELEASE December 2, 2015 CONTACT: Jennifer Werner (202) 226-5181 Cummings Criticizes Fake...

ABBVIE ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR A ONCE-DAILY FORMULATION OF VIEKIRA PAK® (OMBITASVIR, PARITAPREVIR, AND RITONAVIR TABLETS; DASABUVIR TABLETS) TO TREAT GENOTYPE 1 CHRONIC HEPATITIS C VIRUS INFECTION

ABBVIE ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR A ONCE-DAILY FORMULATION OF VIEKIRA PAK® (OMBITASVIR, PARITAPREVIR, AND RITONAVIR TABLETS; DASABUVIR TABLETS) TO TREAT GENOTYPE 1...

GSK Announces Nucala® (mepolizumab), Now Available In The Us For Sub-Group Of Patients With Severe Asthma

RESEARCH TRIANGLE PARK, N.C., Dec. 2, 2015 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Nucala® (mepolizumab), the first and only biologic add-on therapy for people 12...

Propeller Health Announces Development Agreement and R&D Collaboration with GSK to Develop a Digital Sensor for the Ellipta® Inhaler

Partnership reinforces Propeller Health's leadership in respiratory digital health and creates a joint opportunity to advance treatment of respiratory disease through digital innovation MADISON,...

Algorithme Pharma Announces the Appointment of an Executive Vice President, Phase I Clinical Development

Laval, Québec, Canada, November 30, 2015 – Algorithme Pharma of the Altasciences Group, a full service provider focused on early stage clinical research, today announced the addition of...

STAT and Harvard T.H. Chan School of Public Health Release New Poll

FOR IMMEDIATE RELEASE December 1, 2015 Contact: Julie Meyer / SKDKnickerbocker jmeyer@skdknick.com / 202-464-6602 STAT and Harvard T.H. Chan School of Public Health Release New Poll Three Fourths of...

Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for...

Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin

WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 30, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for...

Express Scripts Champions $1 per Pill Access to an Alternative for Daraprim

ST. LOUIS, Dec. 1, 2015 /PRNewswire/ -- Express Scripts (NASDAQ: ESRX) today announced it will partner with Imprimis Pharmaceuticals (NASDAQ: IMMY) to drive access to a low-cost alternative to...

Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies

First and only immunostimulatory antibody approved for multiple myeloma Approval based on ELOQUENT-2, which established the combination of Empliciti with lenalidomide and dexamethasone (Rd)...

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

Ingelheim, Germany, 26. November 2015 – The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of...

Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration

Supported by Phase 3 Studies in Moderate-to-Severe Plaque Psoriasis and Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Nov. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...

Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs of Patients and Growing Importance of Generic Medicines Use in Japan

Date(s): 30-Nov-2015 For a complete listing of our news releases, please click here The Business Venture is Expected to Start Operating in the Second Calendar Quarter of 2016, and will Offer Patients...

Almirall reaches an agreement to acquire 100% of Poli Group

· Agreement to acquire 100% of the share capital of Poli Group Holding S.r.l. · Acquisition will bring added revenues, a growth portfolio and complementary skills in...

Xellia Pharmaceuticals Expands US Production with Acquisition of Manufacturing Plant from Hikma Pharmaceuticals

Xellia Pharmaceuticals Expands US Production with Acquisition of Manufacturing Plant from Hikma Pharmaceuticals Bedford site will significantly strengthen Xellia's manufacturing capacity,...